Boundless Bio initiated with a Buy at H.C. Wainwright

H.C. Wainwright initiated coverage of Boundless Bio (BOLD) with a Buy rating and $5 price target Boundless is a clinical-stage biotechnology company developing novel oncology therapeutics, which are directed at addressing extrachromosomal DNA, the analyst tells investors in a research note. The firm says that with a “lengthy” cash runway extending into 2027, the company has “considerable risk-mitigation, and high upside potential at the current levels.”